skip to main content


Before taking part in the study a full medical history and examination must be taken to ensure that it is safe for you to take part. If eligible for the study you will be treated for 52 weeks with one of the following:

1. Toujeo (insulin glargine)

2. Available "standard of care" insulin

You will continue to take your other non-insulin glucose-lowering medication if appropriate. 

The study consists of 6 clinic visits where we will take blood samples. You must fast for 8 hours before clinic visits.

Overall the duration of the study for each patient is approximately 53 weeks and comprises 3 periods: a 1-week screening period, a 26-week treatment period, and a 26-week extension period.

To take part you must meet the following criteria:

  • Patients with Type 2 diabetes insufficiently controlled with current "standard of care" basal insulin therapy.

  • Fasting plasma glucose >130 mg/dL

If you would like to take part or want more information please contact the study lead:

Study Contact: Chantelle Moorbey


Tel: 02380 475 258

Page Comments